A novel, disruptive vaccination technology: self-adjuvanted RNActive(®) vaccines.
Nucleotide based vaccines represent an enticing, novel approach to vaccination. We have developed a novel immunization technology, RNActive(®) vaccines, that have two important characteristics: mRNA molecules are used whose protein expression capacity has been enhanced by 4 to 5 orders of magnitude by modifications of the nucleotide sequence with the naturally occurring nucleotides A (adenosine), G (guanosine), C (cytosine), U (uridine) that do not affect the primary amino acid sequence. Second, they are complexed with protamine and thus activate the immune system by involvement of toll-like receptor (TLR) 7. Essentially, this bestows self-adjuvant activity on RNActive(®) vaccines. RNActive(®) vaccines induce strong, balanced immune responses comprising humoral and cellular responses, effector and memory responses as well as activation of important subpopulations of immune cells, such as Th1 and Th2 cells. Pre-germinal center and germinal center B cells were detected in human patients upon vaccination. RNActive(®) vaccines successfully protect against lethal challenges with a variety of different influenza strains in preclinical models. Anti-tumor activity was observed preclinically under therapeutic as well as prophylactic conditions. Initial clinical experiences suggest that the preclinical immunogenicity of RNActive(®) could be successfully translated to humans.
CureVac GmbH; Tübingen, Germany.
Karl-Josef
KJ
Kallen
CureVac GmbH; Tübingen, Germany.
Regina
R
Heidenreich
CureVac GmbH; Tübingen, Germany.
Margit
M
Schnee
CureVac GmbH; Tübingen, Germany.
Benjamin
B
Petsch
CureVac GmbH; Tübingen, Germany.
Thomas
T
Schlake
CureVac GmbH; Tübingen, Germany.
Andreas
A
Thess
CureVac GmbH; Tübingen, Germany.
Patrick
P
Baumhof
CureVac GmbH; Tübingen, Germany.
Birgit
B
Scheel
CureVac GmbH; Tübingen, Germany.
Sven D
SD
Koch
CureVac GmbH; Tübingen, Germany.
Mariola
M
Fotin-Mleczek
D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D006801:Humans; D012313:RNA / Q000008:administration & dosage* / Q000276:immunology*; D051199:Toll-Like Receptor 7 / Q000276:immunology; D014611:Vaccination / Q000379:methods; D014765:Viral Vaccines / Q000008:administration & dosage* / Q000276:immunology*
D019496:Cancer Vaccines; D051199:Toll-Like Receptor 7; D014765:Viral Vaccines; D012313:RNA
RNA; vaccines